CC
Caxton Corporation Portfolio holdings
AUM
$4.28M
1-Year Est. Return
131.96%
This Fund
S&P 500
1 Year Est. Return
+131.96%
AUM
$4.28M
AUM Growth
-$18.6M
(-81%)
Holding
14
Top Buys
| 1 | +$233K | |
| 2 | +$56.5K | |
| 3 | +$29.4K | |
| 4 |
Inhibikase Therapeutics
IKT
|
+$19.2K |
Top Sells
| 1 | +$18.7M | |
| 2 | +$268K | |
| 3 | +$173K | |
| 4 |
DFTX
Definium Therapeutics
DFTX
|
+$140K |
| 5 |
SPDR Gold Trust
GLD
|
+$123K |
Sector Composition
| 1 | Healthcare | 27.17% |
| 2 | Financials | 8.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR Gold Trust
GLD
$181B
| $2.76M | 64.5% |
6,964
-322
|
|
||
2
Berkshire Hathaway Class B
BRK.B
$1.04T
| $357K | 8.34% |
710
+59
|
|
||
3
Spyre Therapeutics
SYRE
$3.18B
| $292K | 6.83% |
+8,919
|
|
||
|
DFTX
4
Definium Therapeutics
DFTX
$1.77B
| $210K | 4.91% |
15,688
-11,323
|
|
||
5
Kyverna Therapeutics
KYTX
$482M
| $176K | 4.12% |
18,773
-4,208
|
|
||
6
Compass Therapeutics
CMPX
$1.01B
| $158K | 3.7% |
29,495
-24,008
|
|
||
7
Lexeo Therapeutics
LXEO
$520M
| $138K | 3.24% |
13,943
-3,389
|
|
||
8
X4 Pharmaceuticals
XFOR
$293M
| $62.2K | 1.45% |
+15,557
|
|
||
|
9
Inhibikase Therapeutics
IKT
$235M
| $58.3K | 1.36% |
28,453
+12,060
|
|
||
10
SAB Biotherapeutics
SABS
$185M
| $39.4K | 0.92% |
10,527
-408
|
|
||
11
Context Therapeutics
CNTX
$217M
| $27.1K | 0.63% |
18,403
|
|
||
12
Enliven Therapeutics
ELVN
$1.73B
| – | – |
-13,097
|
|
||
13
Rezolute
RZLT
$297M
| – | – |
-1,986,818
|
|
||
|
BCAX
14
Bicara Therapeutics
BCAX
$993M
| – | – |
-10,941
|
|